Journal of Transplantation / 2011 / Article / Tab 3 / Review Article
The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review Table 3 Univariate analysis for the 3-outcome model of complete, partial response, and no response, to rituximab therapy. Values expressed as median (range) or proportion (%).
Variable Complete response (
) Partial response (
) No response (
)
valueAge at diagnosis (years) 5 (1–33) 7.5 (2–30) 12 (1.9–40) 0.12 Age at transplant (years) 13 (5–48) 22.5 (8–41) 30 (5.5–48) 0.07 Male gender 14/17 (82.4) 2/8 (25) 6/14 (42.8) 0.01 Time to end stage renal disease (years) 3 (0.16–19) 3 (0.6–9) 4 (0.5–12) 0.65 Time to relapse (days) 1 (1–3513) 8 (1–150) 22 (1–828) 0.12 Deceased donor source 11/17 (64.7) 6/8 (75) 10/14 (71.4) 1.00 Serum albumin at relapse (g/dL) 2.7 (1.4–4.4) 3.2 (2–4) 2.3 (1.2–3.3) 0.05 Proteinuria (g/day) 10.25 (1.1–97.4) 5.8 (2–14) 7.64 (2.4–20) 0.19 Plasmapheresis 0.43 <20 treatments 7/17 (41.2) 2/8 (25) 6/14 (42.8) 21–50 treatments 7/17 (41.2) 3/8 (37.5) 2/14 (14.4) >50 treatments 3/17 (17.6) 3/8 (37.5) 6/14 (42.8) Pretransplant plasmapheresis 6/17 (35.3) 1/8 (12.5) 2/14 (14.4) 0.37 Posttransplant plasmapheresis 16/17 (94.1) 8/8 (100) 14/14 (100) 1.00 Rituximab doses 2 (2–6) 3 (1–5) 4 (2–6) 0.03 Time from transplant to rituximab (days) 120 (4–3543) 343 (10–1095) 276 (65–1050) 0.08 Time from relapse to rituximab (days) 62 (3–927) 271 (9–1086) 179 (57–1048) 0.03 Diagnosis of PTLD 2/17 (11.8) 1/8 (12.5) 0/14 (0) 0.41 Cyclophosphamide use 1/17 (5.9) 1/8 (12.5) 2/14 (14.4) 0.81 Tacrolimus use 13/17 (76.5) 8/8 (100) 9/14 (64.3) 0.18 Mycophenolate mofetil use 16/17 (94.1) 8/8 (100) 13/14 (92.8) 1.00